



**7th TRANSLATIONAL RESEARCH E-CONFERENCE
MYELODYSPLASTIC SYNDROMES**

January 28-31, 2021

Chairs: Pierre Fenaux (Paris), Uwe Platzbecker (Leipzig), Mikkael Sekeres (Miami)

Thursday, January 28, 2021

12:50-13:00 Welcome

SESSION I – Etiology of MDS

Chairs: Charlotte Niemeyer (Freiburg) & Austin Kulasekararaj (London)

| | | |
|-------------|---|--|
| 13:00-13:05 | Introduction | Charlotte Niemeyer (Freiburg) Austin Kulasekararaj (London) |
| 13:05-13:20 | Therapy related MDS and other environmental factors in MDS | Maria Teresa Voso (Rome) |
| 13:20-13:35 | Genetic predisposition to MDS and acute leukaemia | Charlotte Niemeyer (Freiburg) |
| 13:35-13:50 | CHIP / functional implications in MDS and AML | Austin Kulasekararaj (London) |
| 13:50-14:05 | Inflammation of HSCs as a potential driver of ineffective hematopoiesis | Marieke Essers (Heidelberg) |
| 14:05-14:20 | Relationships between inherited and acquired predisposition | Jaroslawn Maciejewski (Cleveland) |

SHORT COMMUNICATIONS:

| | | |
|-------------|--|-----------------------------|
| 14:20-14:30 | <i>Leukemogenesis in GATA2 Haploinsufficient Mice Occurs Secondary to Bone Marrow Failure</i> | Miriam Erlacher (Freiburg) |
| 14:30-14:40 | <i>The Genomic Landscape of Myeloid Neoplasms Evolved from Aplastic Anemia/Paroxysmal Nocturnal Hemoglobinuria</i> | Carmelo Gurnari (Cleveland) |
| 14:40-15:10 | <i>Panel discussion</i> | |
| 15:10-15:20 | Coffee Break | |

LIVE Programme

CET Time

SESSION II – Biology of MDS – Genetic Abnormalities

Chairs: Maria (Ken) Figueroa (Miami) & Mikkael Sekeres (Miami)

| | | |
|-------------|--|---|
| 15:20-15:25 | Introduction | Maria (Ken) Figueroa (Miami) Mikkael Sekeres (Miami) |
| 15:25-15:40 | Review of currently available pre-clinical models (including zebra fish) of MDS | Daniel Nowak (Mannheim) |
| 15:40-15:55 | Multiple acquired clonal steps to MDS, molecular architecture and its progression to AML | Olivier Kosmider (Paris) |
| 15:55-16:10 | Druggable molecular targets in MDS and elderly AML (IDH, TP53...) | Torsten Haferlach (Munich) |
| 16:10-16:25 | Epigenetic abnormalities in MDS and their relationship with somatic mutations | Maria (Ken) Figueroa (Miami) |
| 16:25-16:40 | Spliceosome mutations and their consequences in MDS? | Austin Kulasekararaj (London) |

SHORT COMMUNICATION:

| | | |
|-------------|--|-----------------------------|
| 16:40-16:50 | <i>Impact of Somatic Mutations in Myelodysplastic Patients with Isolated Partial or Total Loss of Chromosome 7</i> | <i>Elena Crisà (Novara)</i> |
| 16:50-17:20 | <i>Panel discussion</i> | |

17:25-18:25 SATELLITE SYMPOSIUM:

Title: Ineffective Erythropoiesis: Understanding the biology, optimising clinical practice

Chair: Uwe Platzbecker (Leipzig)

Speakers: Michaela Fontenay (Paris) & Paresh Vyas (Oxford)

MDS Satellite Symposium organized and funded by Celgene | A Bristol Myers Squibb Company

SESSION III – Biology of MDS: Stem Cells and the Microenvironment

Chairs: Hind Medyouf (Frankfurt) & Uwe Platzbecker (Leipzig)

| | | |
|-------------|--|---|
| 18:30-18:35 | Introduction | Hind Medyouf (Frankfurt) Uwe Platzbecker (Leipzig) |
| 18:35-18:50 | The niche in MDS: Inflammation driving evolution | Marc H.G.P. Raaijmakers (Rotterdam) |
| 18:50-19:05 | Bone biology and the osteo-hematopoietic niche | Ulrike Baschant (Dresden) |
| 19:05-19:20 | Hematopoietic stem cells in MDS: The real targets? | Ulrich Steidl (New York) |
| 19:20-19:35 | Mesenchymal stem cells in MDS: The better targets? | Hind Medyouf (Frankfurt) |

LIVE Programme

CET Time

19:35-19:50 Immunological mess in MDS: Is there a target? Shahram Kordasti (London)

19:50-20:20 *Panel discussion*

20:20-20:55 **Controversial debate**
Genetics versus epigenetics in myeloid disease?
Chair: Uwe Platzbecker (Leipzig)

Audience voting

| | | |
|-------------|--------------|------------------------------|
| 20:20-20:25 | Introduction | Uwe Platzbecker (Leipzig) |
| 20:25-20:35 | Genetics | Torsten Haferlach (Munich) |
| 20:35-20:45 | Epigenetics | Maria (Ken) Figueroa (Miami) |

Audience voting

20:45-20:55 *Discussion*

Friday, January 29, 2021

13:00-14:00 3 Simultaneous Meet the Expert sessions

Flow cytometry in MDS
Technical aspects: cytogenetic and mutational analysis
Analysis of somatic mutations, of SNP etc.

Arjan van de Loosdrecht (Amsterdam)
Torsten Haferlach (Munich)
Luca Malcovati (Pavia)

SESSION IV – Diagnostic Workup and Prognostic Factors in MDS

Chairs: Ari Giagounidis (Düsseldorf) & Felicitas Thol (Hannover)

14:05-14:10 Introduction Ari Giagounidis (Düsseldorf)
Felicitas Thol (Hannover)

14:10-14:25 Morphology (including WHO 2018 classification),
cytogenetics and flow cytometry Ari Giagounidis (Düsseldorf)

14:25-14:40 Examining prognostic indicators in MDS Michael Pfeilstöcker (Vienna)

14:40-14:55 Role of comorbidities and quality of life in prognosis.
New evaluation scales (QUALMS...) Reinhard Stauder (Innsbruck)

14:55-15:25 **ROUNDTABLE:**
Response criteria (with recent proposed changes, IWG 2018)
Uwe Platzbecker, Pierre Fenaux, Austin Kulasekararaj, Ari Giagounidis

15:25-15:55 **Controversial debate**
IS NGS useful in MDS?
Chair: Ari Giagounidis (Düsseldorf)

Audience Voting

| | | |
|-------------|--------------------------------|------------------------------|
| 15:25-15:30 | Introduction | Ari Giagounidis (Düsseldorf) |
| 15:30-15:40 | No – Guillermo Sanz (Valencia) | |

LIVE Programme

CET Time

15:40-15:50 Yes – Felicitas Thol (Hannover)

Audience Voting

15:55-16:15 Panel discussion

16:15-17:15 SATELLITE SYMPOSIUM:

Title: Exploring the Immune and Inflammatory Microenvironments in the Search for New Therapies

Chair: Uwe Platzbecker (Leipzig)

Speakers: Raphael Itzykson (Paris), Uwe Platzbecker (Leipzig) & David Valcárcel (Barcelona)

This symposium is organized by NOVARTIS

17:20-17:50 Coffee Break

SESSION V – Specific Subtypes of MDS, based on Morphology and Molecular Biology

Chairs: Michaela Fontenay (Paris) & Eric Solary (Villejuif)

17:55-18:00 Introduction

Michaela Fontenay (Paris)
Eric Solary (Villejuif)

18:00-18:15 MDS with Ring sideroblasts

Michaela Fontenay (Paris)

18:15-18:30 CMML and other MDS/MPNs

Eric Solary (Villejuif)

18:30-18:45 MDS with del 5q

Ari Giagounidis (Düsseldorf)

18:45-19:00 Childhood MDS

Charlotte Niemeyer (Freiburg)

SHORT COMMUNICATION:

19:00-19:10 *IMPACT of RAS-Pathway Activation on Phenotype and Outcome in Patients with Chronic Myelomonocytic Leukemia and a TET2/SRSF2 Comutation* Klaus Geissler (Vienna)

19:10-19:40 *Panel discussion*

Saturday, January 30, 2021

SESSION VI – Treatment of MDS

Chairs: Eva Hellström-Lindberg (Stockholm) & Raphael Itzykson (Paris)

13:30-13:35 Introduction

Eva Hellström-Lindberg (Stockholm)
Raphael Itzykson (Paris)

13:35-13:50 Overview of MDS treatment

Eva Hellström-Lindberg (Stockholm)

LIVE Programme
CET Time

| | | |
|-------------|---|----------------------------|
| 13:50-14:05 | ESA and other growth factors | Valeria Santini (Florence) |
| 14:05-14:20 | HMAs: When and how | Mikkael Sekeres (Miami) |
| 14:20-14:35 | Allo Transplantation: When and how? | Marie Robin (Paris) |
| 14:35-14:50 | Current treatment guidelines for CMML and rare subtypes | Raphael Itzykson (Paris) |

SHORT COMMUNICATION:

14:50-15:00 *Circulating Small Noncoding RNAs As Novel Biomarkers in Myelodysplastic Syndromes* Michaela Merkerova (Prague)

15:00-15:30 *Panel discussion*

15:30-15:40 Coffee break

SESSION VII – Current Progress in the Treatment of MDS
Chairs: Valeria Santini (Florence) & Lionel Adès (Paris)

| | | |
|-------------|--|---|
| 15:40-15:45 | Introduction | Valeria Santini (Florence) Lionel Ades (Paris) |
| 15:45-16:00 | Higher risk MDS: Lessons from elderly AML A renewed role for intensive chemotherapy (CPX 351...)? | Lionel Adès (Paris) |
| 16:00-16:15 | Strategies to improve HMA based therapy | Pierre Fenaux (Paris) |
| 16:15-16:30 | Management of HMA failure | Valeria Santini (Florence) |
| 16:30-16:45 | Novel strategies to treat cytopenia in Low Risk MDS | Uwe Platzbecker (Leipzig) |

SHORT COMMUNICATION:

16:45-16:55 *Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase Ib Study* Andrew Brunner (Boston)

16:55-17:25 *Panel discussion*

17:25-18:25 Poster walk

Leaders for Biology: Michaela Fontenay (Paris) & Torsten Haferlach (Munich)

Leaders for Clinical: Eva Hellström-Lindberg (Stockholm) & Valeria Santini (Florence)

Sunday, January 31, 2021

13:30-14:30 2 Simultaneous Meet the Expert Sessions

Treatment of higher risk MDS
Treatment of lower risk MDS

Mikkael Sekeres (Miami)
Lionel Adès (Paris)

SESSION VIII – Future Treatments and Treatment Strategies in MDS?

Chair: Pierre Fenaux (Paris)

14:35-14:40 Introduction

Pierre Fenaux (Paris)

14:40-14:55 Regulatory issues: registration of drugs in haematology

Axel Glasmacher (Bonn)

14:55-15:25 **ROUNDTABLE:**

Current MDS/CMML clinical trials in Europe

Speakers: Valeria Santini (FISM), David Valcárcel (GESMD), Pierre Fenaux (GFM),
Uwe Platzbecker (GMDS and EMSCO)

15:25-15:40 How to target CHIP?

Klaus Metzeler (Leipzig)

SHORT COMMUNICATION:

15:40-15:50 *Cellular and Murine-PDX Models to Evaluate New Therapies
for Azacitidine-Resistant MDS*

Tomáš Stopka (Prague)

15:50-16:20 *Panel discussion*

SESSION IX – Late-Breaking talks

Chair: Pierre Fenaux (Paris)

16:20-16:25 Introduction

Pierre Fenaux (Paris)

16:25-16:40 Vexas syndrome and MDS

David Beck (Bethesda)

16:40-16:55 MDS/CMML with TET2 or IDH mutations are associated with
Systemic Inflammatory and Autoimmune Diseases and T-cell
Dysregulation

Lin-Pierre Zhao (Paris)

16:55-17:25 *Panel discussion*

17:25 ***Closing Remarks***

Chairs